RESUMEN
The cases study dealt with choosing an individual antiaggregant therapy for patients with instable angina (IA) without lifting the ST segment. Seventy-eight patients with IA, who were treated, apart from routine therapy, by different disaggregants, were examined. The aggregation of platelets was tested on the laser LA 230 "Biola" analyzer, Russia. Aspirin effectively suppressed the adrenalin-induced aggregation of platelets in 20 of 26 patients; cardiomagnil effectively suppressed it in all 17 patients; and plavix reliably reduced the ADP-induced aggregation of platelets. Both types of platelets aggregation were reliably reduced in combined therapy (plavix plus cardiomagnil). Thus, the combined therapy by drugs with different action mechanisms was proven to most effective in patients with IA.
Asunto(s)
Angina de Pecho/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/administración & dosificación , Agregación Plaquetaria/efectos de los fármacos , Quimioterapia Combinada , HumanosRESUMEN
AIM: To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel). MATERIAL AND METHODS: 78 ACS without STSE were randomized into five groups: group 1 patients (n = 17) received no dysaggregants; patients of group 2 (n = 26) received aspirin in the dose 250 mg on the day of admission and then 125 mg/day; group 3 was given cardiomagnil (150 mg on the day of admission and then 75 mg/day, n = 17); group 4--clopidogrel 75 mg/day (n = 7); group 5--combination of clopidogrel 75 mg/day with cardiomagnil 75 mg/day (n = 11). All the patients were administered fraxiparin 86 IU/kg sc each 12 hours for 5-8 days. RESULTS: Group 1 patients showed platelet hyperaggregation, platelet aggregation decreased in groups 2, 3 and 4 (6 patients of group 1 were resistant to aspirin). The highest antiaggregation effect was achieved in group 5. CONCLUSION: Control over antiaggregation treatment in patients with ACS without STSE by monitoring of platelet function open broad opportunities for selection of effective individual therapy.
Asunto(s)
Enfermedad Coronaria/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Ticlopidina/análogos & derivados , Enfermedad Aguda , Aspirina/farmacología , Aspirina/uso terapéutico , Plaquetas/efectos de los fármacos , Clopidogrel , Electrocardiografía , Femenino , Humanos , Masculino , Nadroparina/farmacología , Nadroparina/uso terapéutico , Inhibidores de Agregación Plaquetaria/farmacología , Síndrome , Ticlopidina/farmacología , Ticlopidina/uso terapéuticoAsunto(s)
Infarto del Miocardio/etiología , Deficiencia de Proteína C/complicaciones , Deficiencia de Proteína S/complicaciones , Adulto , Electrocardiografía , Femenino , Fibrinolíticos/administración & dosificación , Fibrinolíticos/uso terapéutico , Humanos , Infarto del Miocardio/sangre , Infarto del Miocardio/diagnóstico , Proteína C/análisis , Deficiencia de Proteína C/sangre , Proteína S/análisis , Deficiencia de Proteína S/sangre , Estreptoquinasa/administración & dosificación , Estreptoquinasa/uso terapéutico , Resultado del TratamientoRESUMEN
Standard kits of reagents, manufactured in the CSSR, intended for measurements of the blood serum and urinary lipids and phosphorus, were used for measurements of these component' concentrations in the bile. The levels of the total lipids and phosphorus in the bladder bile, measured with the use of this kit in normal subjects, did not essentially differ from those reported in literature.